CUL1.MU Stock Analysis
CU
Uncovered
Aspira Women's Health Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 106 full-time employees. The company went IPO on 2000-09-29. Its products include OVA1 and Overa, OVA1plus, Aspira GenetiX and Aspira Synergy. OVA1 is a blood test that is intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical, and Overa is intended to maintain OVA1’s high sensitivity. OVA1plus is a reflex test performed for those OVA1 test results that are in the intermediate risk range. Aspira GenetiX is a genetic test for gynecologic cancer risk, with a focus on female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers. Aspira Synergy is an en-suite, cloud-based technology transfer solution that provides an end-to-end solution from specimen collection to a customized white-label report for clinical laboratories to internalize testing of its products.